{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:14:58Z","timestamp":1778274898684,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1053\/j.ajkd.2018.02.355","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T04:22:22Z","timestamp":1526962942000},"page":"763-765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too\u00a0High?"],"prefix":"10.1053","volume":"71","author":[{"given":"Richard H.","family":"Sterns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2018.02.355_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","article-title":"Vasopressin V2 receptor antagonists","volume":"29","author":"Verbalis","year":"2002","journal-title":"J\u00a0Mol Endocrinol"},{"issue":"1","key":"10.1053\/j.ajkd.2018.02.355_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.4","article-title":"Current treatment practice and outcomes. report of the hyponatremia registry","volume":"88","author":"Greenberg","year":"2015","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2018.02.355_bib3","doi-asserted-by":"crossref","first-page":"537.e9","DOI":"10.1016\/j.amjmed.2015.11.005","article-title":"Diagnosing and treating the syndrome of inappropriate antidiuretic hormone secretion","volume":"129","author":"Verbalis","year":"2016","journal-title":"Am J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2018.02.355_bib4","first-page":"2275","article-title":"Euvolemic hyponatremia in cancer patients. Report of the hyponatremia registry: an observational multicenter international study","volume":"25","author":"Burst","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.ajkd.2018.02.355_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2017.00141","article-title":"Vasopressin receptor antagonists in hyponatremia: uses and misuses","volume":"4","author":"Rondon-Berrios","year":"2017","journal-title":"Front Med"},{"issue":"6","key":"10.1053\/j.ajkd.2018.02.355_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1053\/j.ajkd.2017.12.002","article-title":"Rapidity of correction of hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone following tolvaptan","volume":"71","author":"Morris","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2018.02.355_bib7","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/ndt\/gfp731","article-title":"Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience","volume":"25","author":"Velez","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1053\/j.ajkd.2018.02.355_bib8","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2018.02.355_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1053\/j.ajkd.2018.02.355_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.1988.tb03704.x","article-title":"Osmoregulation of vasopressin secretion and thirst in health and disease","volume":"29","author":"Baylis","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1053\/j.ajkd.2018.02.355_bib11","doi-asserted-by":"crossref","first-page":"E1019","DOI":"10.1152\/ajpendo.00033.2004","article-title":"Downward resetting of the osmotic threshold for thirst in patients with SIADH","volume":"287","author":"Smith","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1053\/j.ajkd.2018.02.355_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0031-9384(87)90212-5","article-title":"Thirst and fluid intake following graded hypohydration levels in humans","volume":"40","author":"Engell","year":"1987","journal-title":"Physiol Behav"},{"issue":"4","key":"10.1053\/j.ajkd.2018.02.355_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/cen.12943","article-title":"Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion","volume":"84","author":"Tzoulis","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1053\/j.ajkd.2018.02.355_bib14","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00228-017-2302-7","article-title":"Low-dose tolvaptan PK\/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults","volume":"73","author":"Shoaf","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1053\/j.ajkd.2018.02.355_bib15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s11739-016-1508-5","article-title":"Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the emergency department","volume":"12","author":"Castello","year":"2017","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1053\/j.ajkd.2018.02.355_bib16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12020-016-0912-y","article-title":"Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH)","volume":"53","author":"Harbeck","year":"2016","journal-title":"Endocrine"},{"issue":"12","key":"10.1053\/j.ajkd.2018.02.355_bib17","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/annonc\/mdr431","article-title":"High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH) [letter]","volume":"22","author":"Kenz","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1053\/j.ajkd.2018.02.355_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13613-015-0096-2","article-title":"Tolvaptan for hyponatremia with preserved sodium pool in critically ill patients.","volume":"6","author":"Umbrello","year":"2016","journal-title":"Ann Intensive Care"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618305511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618305511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:10:13Z","timestamp":1759461013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638618305511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0272638618305511"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.02.355","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too\u00a0High?","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.02.355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.12.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}